Pernix Therapeutics upgraded at Needham As previously reported, Needham upgraded Pernix to Strong Buy from Buy. The analyst said Pernix's purchase of Treximet is a "game changer" and should increase short-term profitability and provides an anchor in the CNS market. Price target raised to $10 from $9.
Pernix Therapeutics price target lowered to $8 from $14 at Brean Capital Brean Capital lowered its price target on Pernix Therapeutics to $8 from $14 to reflect the removal of any growth premium after it was reported that the company will explore strategic alternatives. The firm believes the company's assets are undervalued and the timing of a deal given market volatility is not ideal. Brean Capital maintained its Buy rating on Pernix shares.